Drug Trial Radar · NCT04251117
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Actual
Start
Mar 1, 2020
Primary completion
Nov 29, 2024
Study completion Nov 29, 2028
Sponsor
- Lead sponsor
- Geneos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multi-site Phase I/IIa study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with pembrolizumab (MK-3475) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report.
Conditions
- HCC
Interventions
GNOS-PV02Biological
GNOS-PV02 delivered by intradermal injection and electroporation
INO-9012Biological
INO-9012 delivered by intradermal injection and electroporation
PembrolizumabDrug
Pembrolizumab administered as an intravenous (IV) infusion
CELLECTRA®2000 EP DeviceDevice
CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Related Adverse EventsTime frame: From first study drug administration to approximately 57 months
- Neoantigen-Specific T-Cell ResponseTime frame: From baseline (pretreatment) through on-treatment assessments (approximately up to Week 12), with additional exploratory follow-up time points.
- Immunogenicity of a Personalized Neoantigen DNA Vaccine as Measured by T-cell Activation and Cytolytic Cell Phenotype in PBMCs Using Flow CytometryTime frame: Assessments completed at Weeks 9 or Weeks 12 post-treatment for 4 subjects.
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Johns Hopkins Hospital
Baltimore, Maryland
Icahn School of Medicine at Mount Sinai
New York, New York
Auckland Clinical Studies
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.